Skip to main content

Market Overview

Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount

  • Protalix BioTherapeutics Inc (NYSE: PLXprices the previously announced underwritten public offering of 7.6 million shares at $4.60 per share, a discount of around 21% on the last close of $5.79 on Thursday.
  • Underwriters have an option to purchase up to an additional 1.1 million shares. The offering is expected to close on February 17.
  • Protalix intends to use the net proceeds of around $32.9 million to fund clinical trials for its product candidates, R&D activities, working capital, and general corporate purposes.
  • BofA Securities is acting as the book-running manager, and Oppenheimer & Co. is acting as the co-manager for the offering.
  • Yesterday, Protalix announced an out-licensing pact with SarcoMed U.S.A. to use alidornase alfa in respiratory diseases.
  • Price Action: PLX stock is 18% down at $4.75 in premarket trading on the last check Friday.

Related Articles (PLX)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Offerings General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at